<DOC>
	<DOCNO>NCT01778946</DOCNO>
	<brief_summary>This study ascertain whether nicotine safe tolerable DS patient , help dose-ranging nicotine DS , look evidence enhancement cognitive functioning , establish evidence biological behavioral correlate nicotinic stimulation effect . The knowledge gain translational aspect project may also guide application new nicotinic drug DS generate , first time , data importance nicotinic receptor change development cognitive impairment DS adult . Hypotheses : - Transdermal nicotine treatment well tolerate one month non-smoking DS patient without significant adverse effect . - Nicotine enhance cognitive performance one month compare baseline post-treatment testing . - Nicotine enhance function detectable clinician and/or informant rating ( pre-post ) .</brief_summary>
	<brief_title>Nicotine Treatment Cognitive Decline Down Syndrome</brief_title>
	<detailed_description>Over 50 % adult Down Syndrome ( DS ) develop Alzheimer 's disease ( AD ) age 60 ( Nadel 2003 ) , life expectancy DS 50-60 year . Thus , age-associated cognitive impairment dementia old adult DS urgent public health concern . The investigator propose nicotinic stimulation promise strategy stabilize improve cognitive functioning adult DS , possibly additional neuroprotective effect . The investigator extensive experience investigate role nicotinic receptor human cognition impairment . This application take advantage new insight treat Mild Cognitive Impairment ( MCI-the precursor condition Alzheimer 's Disease ( AD ) typically develop individual ) nicotine propose open label pilot study transdermal nicotine middle-aged non-smoking DS patient show early cognitive and/or behavioral change consistent MCI/dementia . The goal study establish preliminary evidence safety , gain preliminary evidence whether nicotine enhances cognitive functioning DS adult , examine electrophysiological , biological , behavioral correlate nicotinic stimulation effect . The investigator propose positive result cognitive functional index would lead large long double-blind trial test definitively whether nicotinic stimulation may cognitively and/or functionally enhance DS patient . The knowledge gain translational aspect project guide development potentially new nicotinic drug DS generate , first time , data importance nicotinic receptor change development cognitive impairment DS adult . This work also represent first time cutting-edge advance treat MCI/AD general population immediately rigorously applied DS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>Cognitive complaint and/or memory difficulty verify new onset informant . Cognitive Global Rating consistent mild impairment deterioration premorbid baseline . General cognition functional performance sufficiently preserve diagnosis Alzheimer 's disease/dementia make physician time screen visit . No significant cerebrovascular disease : Modified Hachinski score less equal 4 . Age 25+ . Stable medication least 1 month prior screen . Central nervous system ( CNS ) medication stable 3 month . No evidence major depression . Informant available frequent contact subject ( e.g . average 10 hour per week ) . Adequate visual auditory acuity allow neuropsychological testing . Good general health additional disease expect interfere study . Normal B12 , rapid plasma reagin ( RPR ) , Thyroid Function Tests without clinically significant abnormality would expect interfere study . ECG without clinically significant abnormality would expect interfere study . Subject pregnant , lactate . Subjects take drug cholinergic property ( e.g donepezil ) . Agreement take vitamin supplement multivitamin . Negative urine pregnancy test female . Any significant neurologic disease Alzheimer 's disease , Parkinson 's disease , multiinfarct dementia , Huntington 's disease , normal pressure hydrocephalus , brain tumor , progressive supranuclear palsy , seizure disorder , subdural hematoma , multiple sclerosis , history significant head trauma follow persistent neurologic deficit know structural brain abnormality . Active Major depression another major psychiatric disorder describe DSMIV . History alcohol substance abuse dependence within past 2 year ( DSM IV criterion ) . Any significant systemic illness unstable medical condition could lead difficulty comply protocol include : History myocardial infarction past year unstable severe cardiovascular disease include angina congestive heart failure ( CHF ) symptoms rest . Clinically significant obstructive pulmonary disease asthma . Clinically significant unstable gastrointestinal disorder ulcer disease history active occult gastrointestinal bleeding within two year . Clinically significant laboratory test abnormality battery screen test ( hematology , chemistry , urinalysis , ECG ) . Insulinrequiring diabetes uncontrolled diabetes mellitus . Uncontrolled hypertension ( systolic BP &gt; 170 diastolic BP &gt; 100 ) . Use investigational drug within 30 day 5 halflives , whichever longer , prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Nicotine</keyword>
	<keyword>Down Syndrome</keyword>
	<keyword>Mild Cognitive Impairment</keyword>
	<keyword>Event Related Potential</keyword>
	<keyword>Memory</keyword>
	<keyword>Attention</keyword>
	<keyword>Trisomy 21</keyword>
	<keyword>Neuroprotection</keyword>
	<keyword>Cognitive Enhancement</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>APOE</keyword>
</DOC>